AI and Annotated Medical Images – OpenPath, PLIP, and “Medical Twitter”

By Michael Awood

September 1, 2023

The lack of available annotated medical images has historically hindered healthcare innovation. However, a solution is emerging as healthcare professionals start to share anonymised images and insights on public platforms – which includes the social media site previously known as Twitter (X). This has led to the creation of OpenPath, a comprehensive dataset of over 200,000 pathology images coupled with natural language descriptions, marking it as the largest public dataset of its kind.

Researchers have used OpenPath to develop Pathology Language–Image Pre-training (PLIP), a multimodal AI trained on this dataset. PLIP has demonstrated impressive results in zero-shot learning and transfer learning for classifying new pathology images across various tasks. Additionally, PLIP enables users to locate similar cases using either image or natural language search, encouraging knowledge sharing.

The researchers collected over 240,000 public pathology images using popular pathology-related hashtags and expanded the collection with data from other online sources. After thorough data quality checks, they assembled over 200,000 pathology image-text pairs named OpenPath, which they used to develop the versatile PLIP.

PLIP outperformed previous models in tasks such as zero-shot learning, linear probing, and text-to-image and image-to-image retrieval. Unlike other digital pathology machine learning methods, PLIP can adapt to new datasets and provide zero-shot predictions based on any text input, making it a flexible tool for potential new disease subtypes.

The study did note some limitations, including irrelevant data in the image-text pairs and challenges in accounting for varying magnification levels and staining styles. However, researchers are optimistic that PLIP can adjust to images with diverse magnification levels and staining protocols. They expect that OpenPath and PLIP will significantly contribute to advancing AI in pathology and encourage a data-focused approach in this area.

Reference url

Recent Posts

Opdivo lung cancer approval
           

FDA’s Opdivo Lung Cancer Approval

🚀 The FDA has made a groundbreaking move by approving Opdivo (nivolumab) as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). This new regimen, combining Opdivo with platinum-doublet chemotherapy, aims to enhance patient outcomes pre- and post-surgery. With promising results from recent clinical trials, it’s a significant step forward in cancer care!

Learn more about this advancement and its implications for patients.

#SyenzaNews #CancerCare #FDAApproval

Mental Healthcare for Youth
                   

Mental Healthcare for Youth: Addressing Substance Use and Chronic Conditions

🌍🧠 Today, on World Mental Health Day, let’s focus on the mental well-being of our youth. With one in seven adolescents experiencing mental disorders, it’s crucial to address the challenges they face in accessing care. Innovative solutions like telemedicine and school-based programmes offer hope.
Let’s advocate for policies that prioritise youth mental health. Together, we can create a supportive environment for young people to thrive. 🌟
#SyenzaNews #WorldMentalHealthDay #YouthMentalHealth #MentalHealthAwareness

elacestrant breast cancer therapy
         

NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024.

Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare.

#SyenzaNews #BreastCancer #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.